6
Participants
Start Date
November 30, 2010
Primary Completion Date
June 30, 2011
Study Completion Date
July 31, 2011
BN83495
1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
Crozer Chester medical Center, Upland
Dept of Obstetrics and Gynecology, Medical College of Georgia, Augusta
Division of Gynecologic Oncology, University of Minnesota Medical Center, Minneapolis
Jordan Center for Gynecologic Cancer at Penn, University of Pennsylvania, Philadelphia
London Health Sciences Centre, University of Western Ontario, London
Department of Oncology, Ottawa Cancer Center, Ottawa
Dept of Obstetrics and Gynecology, Princess Margaret Hospital, Toronto
CHUM-Hospital Notre-Dame Service de Gynecologic Oncologique, Montreal
Department of Oncology, McGill University, Montreal
Lead Sponsor
Ipsen
INDUSTRY